Reach Us +44 7456035580

Abstract

Tg4010 Vaccine Targeting on NSCLC

Lung cancer is the most common factor of cancer-related deaths and about 85% of lung cancer is non-small cell lung cancer (NSCLC). MUC1, known as the attached protein or trans-membrane protein, is a kind of protein with highly glycosylation (greater than 50%) and high molecular weight (Mr>200*103). MUC1 is overexpressed in many malignancies, and as a tumor-associated antigens (TAAs), it exposes antigenic epitopes and potential T-cell targets. TG4010 vaccine, which encodes as MUC1 tumorassociated antigen and interleukine-2 and targets MUC1, is an effective and promising targeting strategy for patients with advanced NSCLC when in combination with first-line chemotherapy. This review is mainly aiming to focus on the evidence to clinical statistic data of different phases TIME trails for efficacy of TG4010 vaccine immunotherapy observed in NSCLC and some consequent thoughts.


Author(s):

Li Furong and Zheng Yuanyuan



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Recommended Conferences
Flyer image
Abstracted/Indexed in
  • Google Scholar
  • China National Knowledge Infrastructure (CNKI)
  • Cosmos IF
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs